In the SCD-HeFT ( Sudden Cardiac Death in Heart Failure Trial ) , a pre-specified subgroup analysis showed that patients with New York Heart Association functional class III symptoms did not benefit from implantable cardioverter-defibrillator ( ICD ) therapy and appeared to be harmed by amiodarone , whereas New York Heart Association functional class II patients obtained significant survival benefit from ICD .